About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a company based in Menlo Park (United States) founded in 2018. Mirum Pharmaceuticals has raised $120 million across 3 funding rounds from investors including Frazier Healthcare Partners, Oberland Capital and NEA. The company has 322 employees as of December 31, 2024. Mirum Pharmaceuticals has completed 2 acquisitions, including Bluejay Therapeutics and Satiogen. Mirum Pharmaceuticals offers products and services including LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program. Mirum Pharmaceuticals operates in a competitive market with competitors including Alnylam, Ultragenyx, NGM Biopharmaceuticals, BioMarin Pharmaceutical and Nimbus Therapeutics, among others.
- Headquarter Menlo Park, United States
- Employees 322 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mirum Pharmaceuticals, Inc.
-
Annual Revenue
$336.89 M (USD)80.76as on Dec 31, 2024
-
Net Profit
-$87.94 M (USD)46.18as on Dec 31, 2024
-
EBITDA
-$63.98 M (USD)34.93as on Dec 31, 2024
-
Total Equity Funding
$120 M (USD)
in 3 rounds
-
Latest Funding Round
$68.48 M (USD), Post-IPO
Jan 23, 2026
-
Investors
Frazier Healthcare Partners
& 7 more
-
Employee Count
322
as on Dec 31, 2024
-
Investments & Acquisitions
Bluejay Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mirum Pharmaceuticals
Mirum Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol MIRM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mirum Pharmaceuticals
Mirum Pharmaceuticals offers a comprehensive portfolio of products and services, including LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program.
Treatment for cholestasis in rare diseases patients.
Therapy for inborn errors of bile acid metabolism.
Support for genetic neurology conditions in patients.
Program for testing rare diseases through healthcare partners.
People of Mirum Pharmaceuticals
Unlock access to complete
Unlock access to complete
Leadership Team
57 people
Software Development Team
24 people
Sales and Marketing
14 people
Product Management Team
8 people
Finance and Accounting
8 people
Senior Team
8 people
Regional Team
6 people
Board Team
5 people
Unlock access to complete
Funding Insights of Mirum Pharmaceuticals
Mirum Pharmaceuticals has successfully raised a total of $120M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $68.48 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mirum Pharmaceuticals
Mirum Pharmaceuticals has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Frazier Healthcare Partners, Oberland Capital and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for Mirum Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mirum Pharmaceuticals
Mirum Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bluejay Therapeutics and Satiogen.
Investment portfolio details for Mirum Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for infectious diseases treatment are developed.
|
Locked | Locked | 2019 | Locked | |
|
Specialty pharma company focused on developing treatment for
diabetes
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Mirum Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Mirum Pharmaceuticals
Detailed financials for Mirum Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mirum Pharmaceuticals Comparisons
Peer comparison for Mirum Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mirum Pharmaceuticals
Mirum Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, NGM Biopharmaceuticals, BioMarin Pharmaceutical and Nimbus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
Detailed competitors of Mirum Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mirum Pharmaceuticals
Complete news archive for Mirum Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mirum Pharmaceuticals
Mirum Pharmaceuticals was founded in 2018.
Mirum Pharmaceuticals is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Christopher Peetz is the current CEO of Mirum Pharmaceuticals.
Mirum Pharmaceuticals is a funded company, having raised a total of $120M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Mirum Pharmaceuticals is 322.
Annual revenue of Mirum Pharmaceuticals is $336.89M as on Dec 31, 2024.
Mirum Pharmaceuticals was founded in 2018 and is headquartered in Menlo Park, United States. Small molecule therapeutics are developed by the company to address rare diseases, focusing on cholestatic conditions. The lead candidate, Maralixibat, is targeted at Alagille syndrome and progressive familial intrahepatic cholestasis by inhibiting bile acid transport. Volixibat is being advanced for adult cholestasis. Operations center on pharmaceutical research and development in the rare disease sector.
Mirum Pharmaceuticals's top competitors include Alnylam, Nimbus Therapeutics and BioMarin Pharmaceutical.
Mirum Pharmaceuticals offers LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program.
Yes, Mirum Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol MIRM.
Mirum Pharmaceuticals has made 2 acquisitions, including Bluejay Therapeutics, and Satiogen.
Mirum Pharmaceuticals has 8 investors. Key investors include Frazier Healthcare Partners, Oberland Capital, NEA, Deerfield, and Novo Holdings.
The ticker symbol of Mirum Pharmaceuticals is MIRM on NASDAQ.